Arcutis Announces Enrollment of Last Patient in Phase 2a Clinical Trial of ARQ-151 Cream as a Potential Topical Treatment for Atopic Dermatitis
Phase 2a topline data anticipated by year end 2019 ARQ-151 potential "Best in Class" topical PDE4 inhibitor Demonstrated potency advantage...
pcc Practice Builder™ Emerges as a Growth Engine for Medical Practices in 2026